← Leaderboards

Philip Jon Rosenthal

University Of California San Francisco

Google Scholar ↗PubMed ↗ORCID ↗

$36,168,903

Attributed

$42,739,733

Total exposure

19

Grants

10

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.4M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$42,739,733 · 19

By mechanism

R01$24,728,270 · 5

U01$11,549,890 · 3

D43$3,835,299 · 2

R56$1,704,481 · 3

P01$823,615 · 1

R03$73,750 · 1

Top collaborators

Francesca T. Aweeka10 shared
Matthew G Dorsey5 shared

Most similar at University Of California San Francisco

Same institution · by research overlap

Matthew G Dorsey$21,862,621
Francesca T. Aweeka$9,163,452
James H. McKerrow$11,473,832
Sunil Parikh$7,693,164
William R Roush$27,697,643

Others in their field

Top investigators on “Malaria”

Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$82,291,297
Stephen Lev Hoffman · Sanaria, Inc.$79,440,588
Constance Ann Benson · University Of California, San Diego$65,790,143
David Heimbrook · Leidos Biomedical Research, Inc.$61,561,099

Research focus

MalariaAfricaUgandaDrug ResistancePharmaceutical PreparationsResistanceArtemisininsPlasmodium FalciparumAntimalarialsParasitesCombined Modality TherapyBaseCommunicable DiseasesDrug SensitivityResistance MechanismParasite ResistanceLinkFalciparum MalariaSamplingMutationMolecularLaboratoriesProgramsLead

Grant awards (104)

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$461,349

R01 · FY2025 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$127,377

R01 · FY2025 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$97,524

R01 · FY2025 · AI · contact PI

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda$1,252,540

U01 · FY2024 · AI

Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$756,520

R01 · FY2024 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$686,250

R01 · FY2024 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda$656,831

R01 · FY2024 · AI · contact PI

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda$1,177,157

U01 · FY2023 · AI

Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$747,650

R01 · FY2023 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$730,245

R01 · FY2023 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda$656,831

R01 · FY2023 · AI · contact PI

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda$1,181,537

U01 · FY2022 · AI

Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$731,681

R01 · FY2022 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$683,558

R01 · FY2022 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda$656,831

R01 · FY2022 · AI · contact PI

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda$1,197,862

U01 · FY2021 · AI

Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$727,306

R01 · FY2021 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$683,558

R01 · FY2021 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda$656,718

R01 · FY2021 · AI · contact PI

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda$1,194,675

U01 · FY2020 · AI

Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa$759,552

R01 · FY2020 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda$702,709

R01 · FY2020 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$683,345

R01 · FY2020 · AI · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$681,302

R01 · FY2019 · AI · contact PI

Pharmacodynamics of Antimalarial Chemoprevention$670,155

R01 · FY2019 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Therapies$516,144

R01 · FY2019 · AI · contact PI

Training In Malaria Research in Uganda$252,829

D43 · FY2019 · TW · contact PI

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline$755,690

R01 · FY2018 · AI · contact PI

Pharmacodynamics of Antimalarial Chemoprevention$681,596

R01 · FY2018 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Therapies$516,295

R01 · FY2018 · AI · contact PI

Training In Malaria Research in Uganda$252,604

D43 · FY2018 · TW · contact PI

Pharmacodynamics of Antimalarial Chemoprevention$681,596

R01 · FY2017 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Therapies$516,182

R01 · FY2017 · AI · contact PI

Training In Malaria Research in Uganda$253,462

D43 · FY2017 · TW · contact PI

Pharmacodynamics of Antimalarial Chemoprevention$681,596

R01 · FY2016 · AI · contact PI

Discovery of Oxaboroles as New Antimalarial Agents$515,178

R01 · FY2016 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Therapies$512,762

R01 · FY2016 · AI · contact PI

Training In Malaria Research in Uganda$254,321

D43 · FY2016 · TW · contact PI

Pharmacodynamics of Antimalarial Chemoprevention$700,237

R01 · FY2015 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Therapies$575,561

R01 · FY2015 · AI · contact PI

Discovery of Oxaboroles as New Antimalarial Agents$535,298

R01 · FY2015 · AI · contact PI

Training In Malaria Research in Uganda$257,182

D43 · FY2015 · TW · contact PI

Discovery of Oxaboroles as New Antimalarial Agents$577,789

R01 · FY2014 · AI · contact PI

Training In Malaria Research in Uganda$189,904

D43 · FY2014 · TW · contact PI

Discovery of Oxaboroles as New Antimalarial Agents$484,268

R01 · FY2013 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies$468,401

R01 · FY2013 · AI · contact PI

Training In Malaria Research in Uganda$185,990

D43 · FY2013 · TW · contact PI

Discovery of Oxaboroles as New Antimalarial Agents$44,713

R01 · FY2013 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies$498,485

R01 · FY2012 · AI · contact PI

Training In Malaria Research in Uganda$195,778

D43 · FY2012 · TW · contact PI

Discovery of Oxaboroles as New Antimalarial Agents$172,378

R01 · FY2012 · AI · contact PI

Discovery of Oxaboroles as New Antimalarial Agents$718,136

R56 · FY2011 · AI · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies$496,758

R01 · FY2011 · AI · contact PI

Training In Malaria Research in Uganda$195,778

D43 · FY2011 · TW · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies$500,993

R01 · FY2010 · AI · contact PI

Training In Malaria Research in Uganda$195,778

D43 · FY2010 · TW · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies$436,735

R01 · FY2009 · AI · contact PI

Training in Malaria Research in Uganda$133,950

D43 · FY2009 · TW · contact PI

Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies$617,996

R56 · FY2008 · AI · contact PI

Clinical & Molecular Studies of Drug Resistant Malaria$428,734

U01 · FY2008 · AI · contact PI

MALARIA BIOCHEMISTRY AND CELL BIOLOGY$146,913

P01 · FY2008 · AI · contact PI

Training in Malaria Research in Uganda$141,717

D43 · FY2008 · TW · contact PI

Clinical & Molecular Studies of Drug Resistant Malaria$792,106

U01 · FY2007 · AI · contact PI

MALARIA BIOCHEMISTRY AND CELL BIOLOGY$145,301

P01 · FY2007 · AI · contact PI

Biliary Atresia Clinical Research Consortium$140,857

U01 · FY2007 · DK · contact PI

Studies of antimalarial drug efficacy and resistance in Uganda$133,950

D43 · FY2007 · TW · contact PI

Clinical & Molecular Studies of Drug Resistant Malaria$948,773

U01 · FY2006 · AI · contact PI

Biliary Atresia Clinical Research Consortium$227,260

U01 · FY2006 · DK · contact PI

MALARIA BIOCHEMISTRY AND CELL BIOLOGY$148,127

P01 · FY2006 · AI · contact PI

Training in Malaria Research in Uganda$142,500

D43 · FY2006 · TW · contact PI

Clinical &Molecular Studies of Drug Resistant Malaria$912,880

U01 · FY2005 · AI

Falcipain Cysteine Proteases of Malaria Parasites$368,349

R56 · FY2005 · AI

Biliary Atresia Clinical Research Consortium$248,741

U01 · FY2005 · DK

Training in Malaria Research in Uganda$150,000

D43 · FY2005 · TW

MALARIA BIOCHEMISTRY AND CELL BIOLOGY$144,479

P01 · FY2005 · AI

A PROSPECTIVE DATABASE OF INFANTS WITH CHOLESTASIS$4,770

M01 · FY2005 · RR

PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV$1,467

M01 · FY2005 · RR

SAFETY, TOLERANCE AND PK STUDY OF CELLCEPT IN PEDIATRIC LIVER TRANSPLANT$734

M01 · FY2005 · RR

Clinical &Molecular Studies of Drug Resistant Malaria$799,166

U01 · FY2004 · AI

Biliary Atresia Clinical Research Consortium$227,261

U01 · FY2004 · DK

TRAINING IN MALARIA RESEARCH IN UGANDA$199,556

D43 · FY2004 · TW

MALARIA BIOCHEMISTRY AND CELL BIOLOGY$127,059

P01 · FY2004 · AI

Clinical &Molecular Studies of Drug Resistant Malaria$54,985

U01 · FY2004 · AI

Clinical &Molecular Studies of Drug Resistant Malaria$425,656

U01 · FY2003 · AI

EVALUATION OF FALCIPAIN AS AN ANTIMALARIAL DRUG TARGET$339,981

R01 · FY2003 · AI

TRAINING IN MALARIA RESEARCH IN UGANDA$200,000

D43 · FY2003 · TW

Biliary Atresia Clinical Research Consortium$169,850

U01 · FY2003 · DK

TRAINING IN MALARIA RESEARCH IN UGANDA$50,000

D43 · FY2003 · TW

EVALUATION OF FALCIPAIN AS AN ANTIMALARIAL DRUG TARGET$331,735

R01 · FY2002 · AI

Biliary Atresia Clinical Research Consortium$169,850

U01 · FY2002 · DK

TRAINING IN MALARIA RESEARCH IN UGANDA$150,000

D43 · FY2002 · TW

PARASITOLOGY AND CELL BIOLOGY OF MALARIA$0

P01 · FY2002 · AI

SEROPOSITIVITY FOR H PYLORI IN CHILDREN W/ CANCER$0

M01 · FY2002 · RR

EVALUATION OF FALCIPAIN AS AN ANTIMALARIAL DRUG TARGET$319,930

R01 · FY2001 · AI

TRAINING IN MALARIA RESEARCH IN UGANDA$150,000

D43 · FY2001 · TW

PARASITOLOGY AND CELL BIOLOGY OF MALARIA$0

P01 · FY2001 · AI

SEROPOSITIVITY FOR H PYLORI IN CHILDREN W/ CANCER$0

M01 · FY2001 · RR

EVALUATION OF FALCIPAIN AS AN ANTIMALARIAL DRUG TARGET$310,677

R01 · FY2000 · AI

TRAINING IN MALARIA RESEARCH IN UGANDA$150,000

D43 · FY2000 · TW

PARASITOLOGY AND CELL BIOLOGY OF MALARIA$111,736

P01 · FY2000 · AI

MOLECULAR APPROACHES TO DRUG RESISTANT MALARIA$73,750

R03 · FY2000 · AI

SEROPOSITIVITY FOR H PYLORI IN CHILDREN W/ CANCER$17,457

M01 · FY2000 · RR

SEROPOSITIVITY FOR H PYLORI IN CHILDREN W/ CANCER$0

M01 · FY2000 · RR

SEROPOSITIVITY FOR H PYLORI IN CHILDREN W/ CANCER$0

M01 · FY2000 · RR